House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 9, 2014, Pages 1181-1188

  Wang, L ^a   Yin, J ^a   Fadel, R ^b   Montagut, A ^b   De Beaumont, O ^b   Devillier, P ^c  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Stallergenes SA   (France)

^c FOCH HOSPITAL   (France)

Author keywords

asthma; control; house dust mite; sublingual immunotherapy

Indexed keywords

ALLERGEN; HOUSE DUST ALLERGEN;

ADOLESCENT; ADULT; ANIMAL; ASTHMA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PYROGLYPHIDAE; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL IMMUNOTHERAPY; YOUNG ADULT;

ADOLESCENT; ADULT; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYROGLYPHIDAE; SUBLINGUAL IMMUNOTHERAPY; YOUNG ADULT;

EID: 84905868303     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12188     Document Type: Article

References (29)

1. Platts-Mills TAE, Erwin EA, Heymann PW, Woodfolk JA,. Pro: The evidence for a causal role of dust mites in asthma. Am J Respir Crit Care Med 2009; 180: 109-121.
2. Bousquet J, Lockey R, Malling HJ, eds. World Health Organization Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl. 44): 1-42.
3. Calamita Z, Saconato H, Pelá AB, Atallah AN,. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61: 1162-1172.
4. Compalati E, Passalacqua G, Bonini M, Canonica GW,. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-Analysis. Allergy 2009; 64: 1570-1579.
5. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64 (Suppl. 91): 1-59.
6. Radulovic S, Wilson D, Calderõn M, Durham S,. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66: 740-752.
7. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. December 2012 update of the NHLBI/WHO Workshop Report 1995. Available from: http://www.ginasthma.org/.
8. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 43-78.
9. Pedersen S,. From asthma severity to control: a shift in clinical practice. Prim Care Resp J 2010; 19: 3-9.
10. Bateman E, Boushey HO, Bousquet J,. Can guideline-defined asthma control be achieved? Am J Resp Crit Care Med 2004; 170: 836-844.
11. Masoli M, Fabian D, Holt S, Beasley R, for the Global Initiative for Asthma (GINA). The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004; 59: 469-478.
12. Li J, Sun B, Huang Y, Lin X, Zhao D, Tan G, et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy 2009; 64: 1083-1092.
13. Juniper EF, Bousquet J, Abetz L, Batman ED,. Identifying "well-controlled" asthma using the asthma control questionnaire. Respir Med 2006; 100: 616-621.
14. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK,. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
15. Wald A,. Tests of statistical hypotheses concerning several parameters when the number of observations is large. Trans Am Math Soc 1943; 54: 426-482.
16. Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009; 124: 665-670.
17. Cox LS, Larenas-Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS,. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117: 1021-1035.
18. Calderõn MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P,. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67: 302-311.
19. Novak N, Bieber T, Allam JP,. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011; 66: 733-739.
20. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008; 63: S8-S160.
21. Concept paper on the need for revision of the CHMP note for guidance on the clinical development of medicinal products in the treatment of asthma. London, UK, Oct 2009 Draft CPMP/EWP/2922/01. Committee for Medicinal Products for Human Use at the European Medicines Agency. http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2009/10/WC500006234.pdf. Last accessed 5 March 2013.
22. Blumberga G, Groes L, Haugaard L, Dahl R,. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006; 61: 843-848.
23. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C,. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-Avoidance measures. Pediatr Allergy Immunol 2007; 18: 47-57.
24. Gotzsche PC, Johansen HK,. House dust mite control measures for asthma: systematic review. Allergy 2008; 63: 646-659.
25. Pajno GB, Morabito L, Barberio G,. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55: 842-849.
26. Marcucci F, Sensi L, Di Cara G, Salvatori S, Bernini M, Pecora S, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005; 16: 519-526.
27. Tabar AI, Arroabarren E, Echechipia S, Garcbox drawings light down and lefta BE, Martin S, Alvarez-Puebla MJ,. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011; 127: 57-63.
28. Roux M, Yang WH, Viatte A, Cadic V, Abiteboul K, Zeldin, et al. Efficacy of house dust mite sublingual immunotherapy in adults with allergic rhinitis: results of an environmental exposure chamber study. J Allergy Clin Immunol 2013; 131: AB37
29. Demoly P, Bergmann KC, Melac M, Nguyen H, Frereux M, Zeldin RK,. Onset of action of sublingual tablets of house dust mite allergen extracts in adults. J Allergy Clin Immunol 2013; 131: AB37.